Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Mefloquine + Metformin + Temozolomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Mefloquine | Lariam | Mefloquine HCL | ||
Metformin | Glucophage | Apo-Metformin | mTOR Inhibitor 51 | Glucophage (metformin) inhibits part of the mitochondrial respiratory chain and may exert antineoplastic effects through inhibition of mTOR and is FDA approved for type 2 diabetes (FDA.gov). |
Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01430351 | Phase I | Metformin + Temozolomide Mefloquine + Temozolomide Memantine + Metformin + Temozolomide Mefloquine + Memantine + Temozolomide Mefloquine + Memantine + Metformin + Temozolomide Temozolomide Mefloquine + Metformin + Temozolomide Memantine + Temozolomide | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | Active, not recruiting | USA | 0 |